SCHEMBL214692

SCHEMBL214692

NC(=O)OC(=O)[C@@H](N)CC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.35
GABRR1 P24046 2/20 0.34
LMNA P02545 1/20 0.34
GRIK1 P39086 3/20 0.33
GRIA4 P48058 2/20 0.33
GRIK3 Q13003 2/20 0.33
GRIK5 Q16478 2/20 0.33
GRIK2 Q13002 2/20 0.33
GRM1 Q13255 2/20 0.33
GRM2 Q14416 2/20 0.33
GRM8 O00222 1/20 0.33
GRM6 O15303 1/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GSR P00390 1/20 0.33
CYP1A2 P05177 1/20 0.33
GRM5 P41594 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21315720 1.00 TDP1 (0.39) TDP1SLC22A6GABRR1LMNAGRIK1
SCHEMBL1653844 0.88 SLC22A6 (0.39) TDP1SLC22A6GABRR1LMNAGRIK1
Hydrochloric Acid SCHEMBL11804611 0.86 SLC22A6 (0.38) TDP1SLC22A6GABRR1LMNAGRIK1
Aminocarbonyl Dihydrogen Phosphate SCHEMBL21410683 0.86 CA4 (0.50) GRM8GRM6GRM7GRM4
SCHEMBL5221873 0.84 ALOX15 (0.33) CYP1A2ALOX15BLMPMP22KMT2A
SCHEMBL3291829 0.82 ALOX15 (0.32) ALOX15
SCHEMBL21315719 0.82 ALOX15 (0.32) ALOX15
SCHEMBL28002998 0.81 SLC22A6 (0.38) TDP1SLC22A6GABRR1LMNAGRIK1
SCHEMBL62914 0.81 SLC22A6 (0.38) TDP1SLC22A6GABRR1LMNAGRIK1
SCHEMBL1824385 0.80 ALOX15 (0.38) SLC22A6GABRR1LMNAGRIK1GRIA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112779303-A Method for synthesizing orotic acid by biological enzyme method 华东理工大学 2021-05-11 CN claimed
US-7320877-B1 Dihydroorotase extracted from plants BASF AKTIENGESELLSCHAFT (DE) 2008-01-22 US claimed
US-20030096741-A1 Enhanced mineral delivery SLATTERY CHARLES W (US) 2003-05-22 US claimed
EP-1301787-A2 METHOD FOR DETECTING URACIL BIOSYNTHESIS INHIBITORS AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2003-04-16 EP claimed
US-20020058244-A1 Method for detecting uracil biosynthesis inhibitors and their use as herbicides BASF AKTIENGESELLSCHAFT (DE) 2002-05-16 US claimed
WO-2002006512-A2 METHOD FOR DETECTING URACIL BIOSYNTHESIS INHIBITORS AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2002-01-24 WO claimed
US-12590322-B2 Devices and methods for mitochondria replacement and for generating cellular therapeutics NanoCav, LLC (US) 2026-03-31 US disclosed
EP-4687871-A1 TOPICAL PALA THERAPY FOR CANCER The Cleveland Clinic Foundation (US) 2026-02-11 EP disclosed
WO-2025202415-A1 DHODH INHIBITORS FOR USE IN THE CHRONOPHARMACOLIGICAL TREATMENT AND PREVENTION OF OBESITY AND OBESITY-RELATED METABOLIC DISORDERS Institut National de la Santé et de la Recherche Médicale (FR) 2025-10-02 WO disclosed
CN-119286751-B Genetically engineered bacterium for producing uridine diphosphate glucose, construction method and application thereof 诸城市浩天药业有限公司 2025-03-18 CN disclosed
CN-119391619-A Engineering strain for producing uridine diphosphate, construction method and method for synthesizing rebaudioside M 诸城市浩天药业有限公司 2025-02-07 CN disclosed
CN-119286751-A Genetically engineered bacterium for producing uridine diphosphate glucose, construction method and application thereof 诸城市浩天药业有限公司 2025-01-10 CN disclosed
WO-2024206402-A1 TOPICAL PALA THERAPY FOR CANCER THE CLEVELAND CLINIC FOUNDATION (US) 2024-10-03 WO disclosed
WO-2000042213-A1 A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2000-07-20 WO disclosed
EP-0458070-A1 Cytidine analogue resistance gene DNA and its use Takeda Chemical Industries, Ltd. (JP) 1991-11-27 EP disclosed
US-5041542-A Antitumor-anticarcinogenic agents NUCLEIC ACID RESEARCH INSTITUTE (US) 1991-08-20 US disclosed
US-4873228-A 2-oxo-4-carboxy-pyrimidines and their use as anti-malaria and anti-cancer agents THE UNIVERSITY OF MELBOURNE (AU) 1989-10-10 US disclosed
EP-0260057-A2 2-Oxo-4-carboxy-pyrimidines THE UNIVERSITY OF MELBOURNE (AU) 1988-03-16 EP disclosed
US-4550186-A ANTITUMOR, ANTILIPEMIC, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS DUKE UNIVERSITY (US) 1985-10-29 US disclosed
US-4164447-A TRANSFERS A CARBAMOYL GROUP TO 3-HYDROXYMETHYL CEPHALOSPORIN GLAXO LABORATORIES LIMITED (GB) 1979-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058244-A1 Method for detecting uracil biosynthesis inhibitors and their use as herbicides UMPS, UGP2, UNG TDP1 542/4885SLC22A6 2601/4885GABRR1 3905/4885
US-12590322-B2 Devices and methods for mitochondria replacement and for generating cellular therapeutics TFAM, TIMM9, MCU TDP1 874/4885SLC22A6 367/4885GABRR1 2546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.